Studies testing newer P2Y12 inhibitors in acute coronary syndromes showed similar positive effects for ticagrelor and prasugrel on outcomes of patients with DM compared to non-diabetics [1,12]. This evidence concerns the gene P2RY12 and diabetes mellitus.